Medical Doctor Program year 2020 Reported 2019–2020 Source: CMS Open Payments, 2026 publication

Robert Pivec

Adult Reconstructive Orthopaedic Surgery Phoenix, AZ Medical Doctor

NPI 1568773489 CMS profile 521931

5355 E High St Unit 113, Phoenix, AZ 85054

Open in the dashboard

General payments

$1,615

21 records reported · program years 2019–2020

Research payments

$0

Paid to them · None reported · program years 2019–2020

Ownership & investment interest

$0

None reported

Through program year 2020, Robert Pivec of Phoenix, AZ is reported in the CMS Open Payments database as having received $1,615 across 21 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 18th percentile of Adult Reconstructive Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2020 General $434 7
2019 General $1,181 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Pivec
  • Adult Reconstructive Orthopaedic Surgery median
  • Middle half of Adult Reconstructive Orthopaedic Surgery
  • National median

In program year 2025, general payments to Robert Pivec were reported at $0. Among 1,079 Adult Reconstructive Orthopaedic Surgery profiles paid that year, the median was $1,406 and the middle half received between $318 and $8,709.

Show as a table
Year Robert Pivec Adult Reconstructive Orthopaedic Surgery median Middle half National median
2019 $1,181 $1,416 $292–$9,336 $163
2020 $434 $647 $141–$6,474 $114
2021 $0 $1,073 $211–$6,497 $132
2022 $0 $1,217 $236–$6,299 $149
2023 $0 $1,082 $246–$6,818 $160
2024 $0 $1,575 $323–$8,944 $164
2025 $0 $1,406 $318–$8,709 $169

Breakdown

Who paid General payments · program years 2019–2020
  1. Stryker Corporation $979 11 payments
  2. Zimmer Biomet Holdings, Inc. $232 2 payments
  3. Smith+Nephew, Inc. $200 3 payments
  4. AxoGen $123 2 payments
  5. DePuy Synthes Sales Inc. $37 1 payment
  6. Bioventus LLC $29 1 payment
  7. KCI USA, Inc $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2020
  1. Food and Beverage $1,615 21 payments
Products named General payments · program years 2019–2020
  1. ACCOLADE $377 3 payments
  2. T2 $358 3 payments
  3. TRIATHLON $268 2 payments
  4. AXSOS $246 2 payments
  5. HOFFMANN $134 1 payment
  6. EX-FIX $134 1 payment
  7. CORI $131 2 payments
  8. AxoGuard Nerve Connector $123 2 payments
  9. AXOGUARD NERVE PROTECTOR $123 2 payments
  10. Arcos $122 1 payment
  11. Other $716 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

1,791

Median for Orthopedic Surgery: 203

Drug cost

$13,458

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 294 $6,226
Methylprednisolone Generic 307 $2,663
Meloxicam Generic 738 $2,248
Oxycodone Hcl Generic 149 $1,124
Cefadroxil Generic 101 $623
Gabapentin Generic 31 $206
Metoclopramide Hcl Generic 88 $140
Tramadol Hcl Generic 34 $116
Clindamycin Hcl Generic 18 $68
Amoxicillin Generic 31 $43

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$302,620

Of which drugs: $50,864

Medicare patients

661

Average age 75

Services billed

5,195

382 women, 279 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 68%
Ischemic heart disease 25%
Chronic kidney disease 21%
Osteoporosis 20%
Cancer 17%
Diabetes 16%
Depression 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, monovisc, for intra-articular injection, per dose J7327 Office 52 78 $41,921
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 118 382 $1,904
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 73 632 $56

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

21 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Adult Reconstructive Orthopaedic Surgery in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2020

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record